Journal Logo

Articles by Antoine Froissart, MD

Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center

Froissart, Antoine; Buffet, Marc; Veyradier, Agnès; More

Critical Care Medicine. 40(1):104-111, January 2012.